TABLE A18-2Benefit Cohort Population: Individuals and Person Years

Population GroupPopulation SubgroupBenefit Cohort Population Size (2000–2007) (millions)Average Age of MDA Treatment1Average Years of Economic benefit2Person-Years (Lifetime) (millions)3
1. Protected from acquiring infection and subsequent diseasea. Newborns2.24383.8
b. Protected from infection0.5204315.7
Subtotal2.799.5
2. Protected from disease progressiona. Subclinical morbidity9.42043388.6
b. Clinical morbidity19.33033626.6
Subtotal28.71,015.3
Total31.41,114.8
1

Newborns, although not actually treated with MDA, are assumed to be protected from infection at the time of birth and protected from clinical disease from 20 years of age.

2

Based on average life expectancy of 63 years, weighted by country specific rates and Benefit Cohort Population in each country.

3

Sum of each year lived by each individual in the Benefit Cohort Population. Equal to (Benefit Cohort Population) × (Average Years of Economic Benefit), adjusted for annual mortality.

From: A18, THE ECONOMIC BENEFITS RESULTING FROM THE FIRST 8 YEARS OF THE GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS (2000–2007)

Cover of The Causes and Impacts of Neglected Tropical and Zoonotic Diseases
The Causes and Impacts of Neglected Tropical and Zoonotic Diseases: Opportunities for Integrated Intervention Strategies.
Institute of Medicine (US) Forum on Microbial Threats.
Washington (DC): National Academies Press (US); 2011.
Copyright © 2011, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.